You are here
AdvaMed Applauds Outcome Of JCCT In China
WASHINGTON, D.C. – Ralph Ives, executive vice president, global strategy and analysis at the Advanced Medical Technology Association (AdvaMed), today released the following statement in response to the outcome of the 26th U.S.-China Joint Commission on Commerce and Trade (JCCT) in Guangzhou, China, which concluded on Nov. 23.
“AdvaMed applauds the U.S. and Chinese governments, in particular the U.S. Department of Commerce and the U.S. Trade Representative, for achieving concrete outcomes that recognize the importance of improving access for Chinese patients to the life-saving and life-enhancing medical technologies they need. We believe the commitments reached during the JCCT will result in reduced time-to-market for innovative, safe and effective treatments and cures in China. AdvaMed stands ready to support both governments in the implementation of these important JCCT commitments.”
The commitments, which call for treating imported medical technologies the same as those produced in China, further expansion of clinical trial product exemption catalogues, enhancing pre-submission consultation opportunities for medical device applicants, transparent publication of relevant reform measures, and annual performance reports, are outlined by the U.S. Commerce Department here.
# # #